This analysis revealed several distinct DLBCL tumor/immune landscapes: a highly immune-rich subtype characterized by high T-cell-rich CNCs and CD68−CD163+ macrophage-rich CNCs (CNST-1); a tumor-mixed subtype characterized by high dendritic cell-rich and CD68+CD163− macrophage-rich CNCs (CNST-2); a tumor-rich subtype which also has high dual-positive macrophage-rich CNCs (CNST-3); and a subtype dominated by tumor-rich CNC (CNST-4). This evidence concerns the gene CD163 and neoplasm.